Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Clinical perspective on innovative insulin delivery technologies in diabetes management
Avtorji:ID Koçkaya, Güvenç (Avtor)
ID Battelino, Tadej (Avtor)
ID Petrovski, Goran (Avtor)
ID Jendle, Johan (Avtor)
ID Sármán, Beatrix (Avtor)
ID Elbarbary, Nancy (Avtor)
ID Goksen, Damla (Avtor)
ID Alharbi, Mohammed (Avtor)
ID Tibet, Bird (Avtor)
ID Sharaf, Amir Mustapha (Avtor), et al.
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (556,84 KB)
MD5: C924167ED3A7EBFCFDE0531FB81E4DCC
 
URL URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1308319/full
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Introduction: The primary objective of this study is to report the results of an online questionnaire and the in-person discussion sessions of physicians specializing in diabetes care in which their opinions about current diabetes management was obtained. Methods: The Diabetes Innovation Summit 2023 drew attendance from a diverse group of specialized physicians from multiple countries. A comprehensive literature review was conducted to examine the technologies and medical needs associated with diabetes management. Using the results of the review, a questionnaire was developed by three experts from the steering committee to solicit feedback from specialized physicians. The online survey was made accessible between 10th December 2022 and 10th January 2023. Following the online survey, six structured in-person discussion sessions were conducted with specialized physicians from the Middle East, Central-Eastern Europe, and North Africa regions. Results: The study revealed that about 59% of survey requests were answered, with many participants being pediatric endocrinologists from North Africa. Around 60% of diabetes patients followed Multiple Daily Injections (MDI) according to specialized physicians. Among MDI users, 62% employed Blood Glucose Monitors (BGM), 31% used intermittent-scanning Continuous Glucose Monitors (isCGM), and 23% used CGM. In North Africa, nearly 90% of patients used MDI due to financial constraints. While physicians focused on both Time in Range (TIR) and HbA1c for MDI-treated patients, satisfaction with TIR achieved was expressed by 31%, while 74·1% believed Real-Time CGM (rtCGM) was effective. Concerns arose about potentially misleading HbA1c results and the relatively low patient achievement of target TIR despite CGM usage. The Smart MDI System was seen favorably compared to other applications. The system’s affordability was a significant barrier, particularly in the Middle East and Africa. Conclusion: The present study highlights that physicians are generally supportive of utilizing new technology. The questionnaires and the open discussion revealed the expectation that the Smart MDI technology provides better control, primarily by identifying missed boluses, while expressing concerns on the use of the technology by teenagers and children, who might forget the device and be reluctant to use in public, and by the older population, who might be challenged by the technology
Ključne besede:diabetes treatment, glycemic control
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:str. 1-10
Številčenje:Vol. 15
PID:20.500.12556/DiRROS-29844 Novo okno
UDK:61
ISSN pri članku:1664-2392
DOI:10.3389/fendo.2024.1308319 Novo okno
COBISS.SI-ID:213510403 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 3. 11. 2024;
Datum objave v DiRROS:08.06.2026
Število ogledov:75
Število prenosov:49
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Frontiers in endocrinology
Založnik:Frontiers Research Foundation
ISSN:1664-2392
COBISS.SI-ID:3340154 Novo okno

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj